Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Peter Kushner"'
Autor:
Alison D. Parisian, Gopinath S. Palanisamy, Fabian Ortega, Judevin L. Sapugay, William J. Bodell, David Kulp, Peter Kushner, Cyrus Harmon
Publikováno v:
Cancer Research. 83:P2-24
OP-1250, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), is currently in Phase I/II clinical trials for the treatment of estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::526452b217a6393c2668674e158b2633
https://doi.org/10.1158/1538-7445.sabcs22-p2-24-07
https://doi.org/10.1158/1538-7445.sabcs22-p2-24-07
Autor:
Manish Patel, Carlos Alemany, Zahi Mitri, Della Makower, Virginia Borges, Joseph Sparano, Trinh Le, Pamela Klein, Julia Lawrence, Peter Kushner, Demiana Faltaos, Cyrus Harmon, David Myles, JoAnne Zujewski, Erika Hamilton
Publikováno v:
Cancer Research. 82:P1-17
Background: ER+, HER2- metastatic breast cancer (MBC) patients will receive sequential, endocrine based therapy, either as monotherapy or in combination with a targeted agent until endocrine resistance develops. OP-1250 is a small molecule Complete E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1d893f422085d5460b5d7a2022ee7ba
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-12
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-12
Publikováno v:
Breast Cancer Research & Treatment; May2008, Vol. 109 Issue 2, p241-250, 10p, 6 Graphs
Publikováno v:
Breast Cancer Research & Treatment; Nov2007, Vol. 105 Issue 3, p297-309, 13p